Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug
about
Stromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic TargetRapalogs in cancer prevention: anti-aging or anticancer?Mitochondrial DNA Damage and DiseasesBig mice die young but large animals live longerEthanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer preventionContact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence programLatest progress in tyrosine kinase inhibitorsTumor-fibroblast interactions stimulate tumor vascularization by enhancing cytokine-driven production of MMP9 by tumor cells.Caloric restriction delays early phases of carcinogenesis via effects on the tissue microenvironment.Metformin limits the adipocyte tumor-promoting effect on ovarian cancer.TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Selective anti-cancer agents as anti-aging drugsCatalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Gerosuppression in confluent cells.Targeting the tumor microenvironment to enhance antitumor immune responsesPrimed for cancer: Li Fraumeni Syndrome and the pre-cancerous nicheTargeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.Comparison of rapamycin schedules in mice on high-fat diet.Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?Koschei the immortal and anti-aging drugsActivation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in miceRapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumorsTemporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development.Li Fraumeni syndrome, cancer and senescence: a new hypothesis.Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomideRecent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer.Targeted therapy for breast cancer prevention.Rapamycin extends life- and health span because it slows aging.Rapamycin suppresses brain aging in senescence-accelerated OXYS rats.Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo.
P2860
Q26797288-B88C2042-2191-4FC6-9042-0CA25D7FA869Q26866151-BB47E117-9107-4C65-BF8A-9C42B73439E7Q27007991-63CBAD42-1DC7-42A7-9FDE-F19450946C22Q28704146-3334CDF3-9C06-4E06-A9E7-2546CCEDF4C9Q28708831-FF2D440A-9EE3-43BE-8376-289CF6B9DCBBQ28972583-5CF3E1CF-6813-4537-A1BE-E8EED01AD44BQ33576849-355B70F0-9A75-4CFF-BA58-E4C4E97D1D70Q33829243-653C52A0-1D9C-4B7D-BFF5-76AA70E98930Q33829389-683C6A59-BFF3-4F79-A47D-DE3295DF01DFQ34104019-16338BA4-8D73-4380-888C-CABBFB017E23Q34391710-45B7F39E-6C51-47E3-AEDB-47F6F8AF4FA1Q34392470-74970759-9B3C-4492-BB9A-ADE425CBF1B8Q34483665-3385B2D2-0338-44B2-A91E-04CD3BC292AEQ34957090-2320FA3D-035D-4F1B-87E0-F2A7A17B7589Q34982499-FED98479-60C4-44BA-B044-6B46D458B49FQ35176307-E6ABA23A-B5E0-4BA9-AFBC-03D4BA75EB21Q35717532-B143EABC-0BD2-4F42-899D-9A437246BBCFQ35741514-B14C1E67-E5E9-4897-BAA6-4DDFC718BA63Q36020888-D8865BF4-0A23-498B-A221-7DCEE1D13F48Q36186386-7F646873-CCFD-445F-BD32-55F413A01F22Q36189078-18EAEA1D-02D2-46C3-AD9F-E8DD322808C2Q36209128-1140F81F-BA38-4B7A-9E8A-D4F417119AB4Q36292001-98592DF1-DF64-4A58-BFEC-A3EC38F82205Q36355880-14CBF5CF-1E23-475A-A263-958C3A60099DQ36414149-D5959AE6-C648-4D1A-950F-86D4FACB4FA4Q36414376-F26C46DE-777E-405A-8BB1-F2269265AF4EQ36426491-ACEAE5F9-31EC-4151-87D8-B89AA6C178C3Q36544718-1E2AA913-A27F-4142-BEFD-A672590485F6Q36739314-10FD5AD5-B359-431F-9E2E-0B55ADBD47F2Q36739319-ECCE41F4-28C8-4F23-8506-7A05BD4FF69AQ36797708-EDCFDCCF-9A98-4574-8689-1B277F87CA7DQ36923326-E19C756D-A214-476F-AE43-4323627EA077Q36926098-AD342062-671A-426E-981B-543D44ED9693Q36926148-2DBCE391-9680-4C2F-A5DE-E5D185DF55ADQ37062514-6DB34E00-E611-4DDA-81FB-CC1B5820CFE2Q37075896-F0606E68-920F-43FC-B68F-B8B313376C16Q37190825-05830187-C5D3-4F42-8BA8-4BA989168A8CQ37228766-9889D837-2AFE-420F-852E-71FEC9AB67BEQ37298898-0120373E-6A47-434B-AE8F-95D69EFAE44DQ37344807-9994546C-CDAD-40D5-AAED-B57983CAB019
P2860
Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@ast
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@en
type
label
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@ast
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@en
prefLabel
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@ast
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@en
P2093
P2860
P50
P1476
Caveolin-1 and accelerated hos ...... inhibitor and anti-aging drug
@en
P2093
Alexander Molchansky
Donna M Gonzales
Isabelle Mercier
Janet N Milliman
Jean-François Jasmin
Jeanette Camacho
Kanani Titchen
Kelly G Bryant
Kevin Quann
Richard G Pestell
P2860
P304
P356
10.1016/J.AJPATH.2012.03.017
P407
P577
2012-06-13T00:00:00Z